Typewriter Therapeutics Emerges From Stealth with $56M Series A Funding and Key Appointments

Biotech company Typewriter Therapeutics secures $56 million in Series A financing and appoints new CEO, CSO, and board members. The company's technology focuses on creating safer genetic medicines for cancer, autoimmune diseases, and severe genetic diseases.

Citation:
[1] Prnewswire Venture Capital